Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal. H.C. Wainwright analyst Andrew Fein ...

I n a challenging market environment, Alector Inc (NASDAQ:ALEC) stock has touched a 52-week low, sinking to $1.59. With a market capitalization of $158.65 million, InvestingPro analysis suggests ...

Alector (ALEC) announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of ...

Alector has launched an $208 million stock market offering as it ramps up clinical trials with AbbVie into a drug that aims to tackle Alzheimer’s by modifying the brain’s immune system.

Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- "It has been a privilege to work alongside the talented team at Alector to advance a pipeline of therapies designed to ...

Alector said Gary Romano is stepping down as medical chief after about three years in the role, and will be replaced by Giacomo Salvadore. The late-stage clinical biotechnology company with a ...

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

with approximately 75% targe Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal. SOUTH SAN ...